Search research articles
Contact Us
Filters
Showing results (21-30 of 31) with videos related to
Page
of 4
Sort By:
NPJ Parkinson'S Disease
|
January 27, 2023
Computer vision quantification of whole-body Parkinsonian bradykinesia using a large multi-site population
Gareth Morinan, Yuriy Dushin, Grzegorz Sarapata, et al.
Brain : a Journal of Neurology
|
May 7, 2026
Clinical prognostic indicators in multiple system atrophy
Yee Yen Goh, Viorica Chelban, Nirosen Vijiaratnam, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
May 28, 2026
Observations on an Open-Label Phase 1/2 Dopamine Gene Therapy Trial (OXB-102/Axo-Lenti-PD) in People with Parkinson's Disease
Simon Rowe, Amy Evans, Saeed Kayhanian, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
May 16, 2022
Combining biomarkers for prognostic modelling of Parkinson's disease
Nirosen Vijiaratnam, Michael Lawton, Amanda J Heslegrave, et al.
BMJ Neurology Open
|
July 6, 2026
Identifying and predicting fast versus slow Parkinson's disease motor progressors using clinical and digital data
Timothee Aubourg, Katarina M Gunter, Christine Lo, et al.
BMJ Open
|
May 29, 2021
Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinson's disease: protocol for a multicentre, randomised, double blind, parallel group, placebo controlled, phase 3 trial: The 'Exenatide-PD3' study
Nirosen Vijiaratnam, Christine Girges, Grace Auld, et al.
Journal of Parkinson'S Disease
|
October 3, 2025
Quantitative measurements of α-synuclein seeds in CSF inform diagnosis of synucleinopathies
Ilham Y Abdi, Indulekha P Sudhakaran, Simona S Ghanem, et al.
Annals of Neurology
|
July 29, 2025
Exenatide Once Weekly in the Treatment of Patients with Multiple System Atrophy
Nirosen Vijiaratnam, Christine Girges, Martin Wiegand, et al.
Lancet (London, England)
|
February 7, 2025
Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial
Nirosen Vijiaratnam, Christine Girges, Grace Auld, et al.
The Lancet. Neurology
|
June 20, 2025
Diagnostic and prognostic value of α-synuclein seed amplification assay kinetic measures in Parkinson's disease: a longitudinal cohort study
Christina D Orrú, David P Vaughan, Nirosen Vijiaratnam, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 31) with videos related to
Sort By:
Page
of 4
NPJ Parkinson'S Disease
|
January 27, 2023
Computer vision quantification of whole-body Parkinsonian bradykinesia using a large multi-site population
Gareth Morinan, Yuriy Dushin, Grzegorz Sarapata, et al.
Brain : a Journal of Neurology
|
May 7, 2026
Clinical prognostic indicators in multiple system atrophy
Yee Yen Goh, Viorica Chelban, Nirosen Vijiaratnam, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
May 28, 2026
Observations on an Open-Label Phase 1/2 Dopamine Gene Therapy Trial (OXB-102/Axo-Lenti-PD) in People with Parkinson's Disease
Simon Rowe, Amy Evans, Saeed Kayhanian, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
May 16, 2022
Combining biomarkers for prognostic modelling of Parkinson's disease
Nirosen Vijiaratnam, Michael Lawton, Amanda J Heslegrave, et al.
BMJ Neurology Open
|
July 6, 2026
Identifying and predicting fast versus slow Parkinson's disease motor progressors using clinical and digital data
Timothee Aubourg, Katarina M Gunter, Christine Lo, et al.
BMJ Open
|
May 29, 2021
Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinson's disease: protocol for a multicentre, randomised, double blind, parallel group, placebo controlled, phase 3 trial: The 'Exenatide-PD3' study
Nirosen Vijiaratnam, Christine Girges, Grace Auld, et al.
Journal of Parkinson'S Disease
|
October 3, 2025
Quantitative measurements of α-synuclein seeds in CSF inform diagnosis of synucleinopathies
Ilham Y Abdi, Indulekha P Sudhakaran, Simona S Ghanem, et al.
Annals of Neurology
|
July 29, 2025
Exenatide Once Weekly in the Treatment of Patients with Multiple System Atrophy
Nirosen Vijiaratnam, Christine Girges, Martin Wiegand, et al.
Lancet (London, England)
|
February 7, 2025
Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial
Nirosen Vijiaratnam, Christine Girges, Grace Auld, et al.
The Lancet. Neurology
|
June 20, 2025
Diagnostic and prognostic value of α-synuclein seed amplification assay kinetic measures in Parkinson's disease: a longitudinal cohort study
Christina D Orrú, David P Vaughan, Nirosen Vijiaratnam, et al.
Page
of 4